<DOC>
	<DOCNO>NCT00816582</DOCNO>
	<brief_summary>Purpose : To determine whether [ 18F ] FES predict clinical benefit ( define complete response , partial response stable disease ≥ 6 month ) fulvestrant ( 250 mg IM q 28 day ) post-menopausal woman recurrent metastatic ER+ breast cancer candidate hormonal therapy .</brief_summary>
	<brief_title>PET/CT Guided Fulvestrant Therapy Patients With Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>The majority woman diagnose breast cancer post-menopausal , 75 % estrogen ( ER ) and/or progesterone receptor ( PR ) positive . Even pre-menopausal breast cancer half patient expression hormone receptor . Thus therapeutic strategy target estrogen receptor ligand common treatment offer breast cancer . Despite substantial benefit demonstrate selective estrogen receptor modulators ( e.g . tamoxifen ) aromatase inhibitor ( e.g . anastrazole , letrozole exemestane ) , significant proportion patient still unfortunately develop resistance hormonal therapy . Despite approximately two-thirds patient prescribe fulvestrant follow prior hormonal agent benefit therapy , clinician still offer option suitable woman lack good mean identify individual responder . To assess whether recommended treatment beneficial specific individual , disease burden assess follow treatment . Conventional image technique bone scan computerize tomography ( CT ) take several month show successful response treatment . Positron emission tomography ( PET ) improve evaluation woman breast cancer provide accurate assessment extent disease unique information tumor biology metabolic activity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>postmenopausal ( ≥ 60 year old , age ≥ 45 year amenorrhea &gt; 12 month follicle stimulate hormone estrogen level within postmenopausal range , prior bilateral oophorectomy ) hormone receptor positive ( ER and/or PgR ) disease determine locally WHO performance status 02 life expectancy ≥ 3 month presence least one measurable evaluable ( nonmeasurable ) lesion inform consent prior study procedure life threaten metastatic visceral disease brain leptomeningeal metastases prior exposure fulvestrant history bleed diathesis need long term anticoagulation</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Post-menopausal hormone receptor positive recurrent/metastatic breast cancer .</keyword>
	<keyword>PET/CT</keyword>
	<keyword>Recurrent metastatic</keyword>
</DOC>